Kat Langford

Kat is a patent attorney in the Life Sciences – Biotechnology group. She has worked across a broad range of technologies, including therapeutic antibodies, vaccines and other immunotherapies, biomarkers, gene editing and viral gene therapy vectors. Kat has experience attacking and defending patents, including in multi-party proceedings at the EPO, both at first instance and on appeal. Her work includes strategic management of large global patent portfolios, and she has also been involved in UPC litigation at the UPC.

Kat graduated from the University of Cambridge with a first class degree in Natural Sciences, specialising in pathology. Her post-graduate research, conducted as part of the Wellcome Trust Infection & Immunity PhD programme, focussed on the molecular mechanism of genome packaging in influenza A virus.

Kat joined Carpmaels & Ransford in 2021, having entered the patent profession in 2012. She is a qualified UK and European patent attorney. As part of her qualification, she was awarded the GlaxoSmithKline Prize at Queen Mary University of London for the highest mark in the patents examinations. She was also awarded the Ballantyne Prize by the UK Chartered Institute of Patent Attorneys for the highest mark in the Validity & Infringement examination.

In her spare time, Kat enjoys riding horses and walks in the countryside.